The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the Vyleesi label, and added the Drugs@FDA approval record and FDA’s October 22, 2026 approval of a labeling supplement. 134
What this version reported
Two large randomized trials described in the label found small improvements in desire and distress scores but no difference in satisfying sexual events. The label states that it is contraindicated in uncontrolled high blood pressure or known cardiovascular disease.↗
Reader guide in this version
Key takeaway
Bremelanotide is a lab-made peptide that activates melanocortin receptors and is the active ingredient in Vyleesi.1,3 It is FDA-approved for one use: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The label states that it is not indicated for postmenopausal women, for men or to enhance sexual performance.1 Two large randomized trials described in the label found small improvements in desire and distress scores, but no difference from placebo in the number of satisfying sexual events.1 Nausea affected 40% of people taking it in those trials, and the label says it is contraindicated in people with uncontrolled high blood pressure or known heart disease.1
At a glance
- What it is
- A melanocortin receptor agonist. The label states that it activates several receptor subtypes, of which MC1R and MC4R are most relevant.1
- FDA status
- FDA-approved. Drugs@FDA lists Vyleesi with an original approval date of June 21, 2019, for HSDD in premenopausal women. The cited label has no boxed warning.1,3
- Human evidence
- Two identical 24-week randomized, double-blind, placebo-controlled Phase 3 trials described in the label.1
- Evidence strength
- Large randomized human trials
What is bremelanotide?
Bremelanotide is a lab-made peptide that the label describes as a melanocortin receptor agonist. It is also known by its development code, PT-141.1,2
In the United States it is the active ingredient of Vyleesi, according to Drugs@FDA.3
How does bremelanotide work?
The label states that bremelanotide activates several melanocortin receptors and that, at the levels used, binding to MC1R and MC4R is most relevant. MC4R-carrying nerve cells are found in many parts of the brain.1
The label also states that the way it improves HSDD in women is unknown, and that binding to MC1R on pigment cells can increase skin pigmentation.1
What do human studies show?
The label describes two identical randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized HSDD, in which 1,267 participants were randomized to bremelanotide or placebo for 24 weeks.1
In both trials, bremelanotide produced a statistically significant increase in a sexual-desire score and a decrease in a score for distress about low desire compared with placebo, according to the label.1
The label reports no significant difference from placebo in the number of satisfying sexual events, a secondary measure.1
More people stopped treatment early in the bremelanotide groups than in the placebo groups: 40% versus 13% in one trial and 39% versus 25% in the other. In the trials, 18% of people taking bremelanotide stopped because of adverse reactions, most often nausea, compared with 2% on placebo.1
What the evidence base contains
- Large randomized human trial Two identical randomized, double-blind, placebo-controlled Phase 3 trials (NCT02333071 and NCT02338960) that together randomized 1,267 participants, all premenopausal women with acquired, generalized HSDD, with a 24-week placebo-controlled phase.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Is bremelanotide FDA-approved?
Yes. Drugs@FDA lists Vyleesi, application NDA210557, with an original approval date of June 21, 2019.3
The Vyleesi label cited here (DailyMed SPL version 1, published November 18, 2025) states that it is indicated for premenopausal women with acquired, generalized HSDD that causes marked distress or difficulty in relationships and is not due to another medical or psychiatric condition, relationship problems or the effects of a medicine.1
The label states that it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance.1
The label has no boxed warning. It states that bremelanotide is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease, and its warnings cover temporary rises in blood pressure with a fall in heart rate, darkening of patches of skin and gums, and nausea.1
On October 22, 2026, FDA approved a labeling supplement for Vyleesi that, according to the approval letter, updates the label’s section on use in specific populations based on the final report of a required postmarketing study.4
What is still unknown?
How bremelanotide improves HSDD, which the label says is unknown.1
How meaningful the score changes are for individual women: the label presents supplementary analyses to help interpret them, and many participants stopped treatment early.1
Its effects outside the approved population: the label’s trials enrolled premenopausal women only.1
Sources for this version
- 1VYLEESI (bremelanotide) injection · SPL version 1 · published 2025-11-18 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Bremelanotide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked July 29, 2026
- 3Drugs@FDA application NDA210557 · original submission status AP · 2019-06-21 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Vyleesi (bremelanotide): NDA 210557 supplement S-005 approval letter, October 22, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026